Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

GSK plans sirukumab filing in rheumatoid arthritis next year

Says phase III trials showed 'no unexpected safety findings'

- PMLiVE

ViiV agrees $1.5bn deal to acquire BMS’ HIV assets

Includes its entire development pipeline - from discovery to preclinical projects

- PMLiVE

Turing CEO Shkreli arrested by FBI in securities fraud probe

Accused of illegally using stock from biopharma firm Retrophin to pay off debts

Lucid group celebrate their outstanding year in style at The Shard

A fabulous montage from our end of year meeting at The Shard. Celebrating our achievements the Lucid way.

Lucid Group Communications Limited

Gilead Sciences

Gilead steps into breach left by AbbVie as Galapagos’ partner

Deal worth $2bn to help rheumatoid arthritis drug filgotinib make it through to the market

- PMLiVE

The gestalt of communications

Why integrated communications results are superior to the sum of their parts 

- PMLiVE

NHS patients set to be denied Opdivo and Kadcyla

NICE rejects BMS and Roche cancer treatments

Eli Lilly HQ

Lilly’s Lantus ‘follow-on’ approved in the US

Basaglar is first insulin product to be licensed via the FDA's truncated 505(b)(2) pathway

- PMLiVE

AZ takes majority stake in cancer drug developer Acerta

Will pay $4bn for a 55% share in the Dutch biopharma company

- PMLiVE

MSD appoints Jessica Fine as UK external affairs director

She joins the UK pharma company from Lexington Health

Lucid group celebrate outstanding year in style

A well-deserved celebration

Lucid Group Communications Limited

China flag thumb

AstraZeneca sets sights on China with Takeda deal

Buys the Japanese firm's respiratory drugs to extends their ongoing biologics R&D collaboration

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links